Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Der p 2 is a major allergen protein derived from the house dust mite Dermatophagoides pteronyssinus. It belongs to the NPC2 family and contains an MD-2-related lipid recognition (ML) domain. The protein has a molecular weight of approximately 14–15 kDa and is found in high concentrations in the digestive tract and fecal pellets of D. pteronyssinus. Structurally, it is a single-domain β-sandwich protein stabilized by three disulfide bonds and features a hydrophobic cavity that binds aliphatic chains. Der p 2 mimics human MD-2 (a co-receptor for Toll-like receptor 4), allowing it to interact with the innate immune system and contribute to allergic sensitization. Exposure to Der p 2 is highly predictive of immediate asthmatic responses in sensitized individuals; IgE reactivity rates among house dust mite-allergic patients are very high (upwards of ~80–100%). It exhibits strong cross-reactivity with other group 2 allergens such as Der f 2 from Dermatophagoides farinae[3][5][2]. Recombinant or purified natural forms are used for research, diagnostics, and as components in allergen-specific immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Der p 2.